Robert Fenstermaker

MD
Neurosurgery
2023 Buffalo Spree Top Doctors Badge

Dr. Fenstermaker is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2023

Cancers Treated:

Brain

Specializing In:

Brain Tumor Surgery Skull Base Surgery Pituitary Tumor Surgery Trigeminal Neuralgia Gamma Knife Radiosurgery

Research Interests:

Immunotherapy for the treatment of malignant brain tumors

About Robert Fenstermaker

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Neurosurgery and Oncology
  • Chair, Department of Neurosurgery
  • Director, Neuro-Oncology Program

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Department of Neurosurgery

Background

Education and Training:

  • MD - Northeast Ohio Medical University, Rootstown, OH

Residency:

  • University Hospitals of Cleveland and Case Western Reserve University School of Medicine, Cleveland, OH

Fellowship:

  • Case Western Reserve University School of Medicine (Biochemistry and Pharmacology) Cleveland, OH

Board Certification:

  • Neurological Surgery, American Board of Neurological Surgery
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Learn More

Clinical Trials

Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Learn More
National spotlight for a homegrown innovation Oligodendroglioma: Josh’s story Surviving a benign brain tumor: Peter’s story Is meningioma cancer? New Surgical Technology Gives Neurosurgeons a Sharper, Broader View Does Brain Cancer Run in Families? Roswell Park Launches Immunotherapy Clinical Trials for Multiple Myeloma Low-Grade Glioma Buffalo Goes Gray for Brain Cancer Research If a Brain Tumor is Not Cancerous, Why Do Anything About It? Understanding Brain Tumors: The Basics Clyde's Story: Surviving a Cancerous Brain Tumor What Is "Orphan Drug Status?" Creating a Vaccine for Aggressive Brain Cancers Roswell Park Researchers Test Brain Cancer Vaccine in Phase I Trial

Featured on Cancer Talk

National spotlight for a homegrown innovation
Oligodendroglioma: Josh’s story
Surviving a benign brain tumor: Peter’s story

Showing all3 of 15

Publications

Full Publications list on PubMed
  1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J 3rd, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345.
  2. Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016 Nov;65(11):1339-1352.
  3. Rivers C, Tranquilli M, Prasad S, Winograd E, Plunkett RJ, Fenstermaker RA, Fabiano AJ, Podgorsak MB, Prasad D. Impact of the Number of Metastatic Tumors Treated by Stereotactic Radiosurgery on the Dose to Normal Brain: Implications for Brain Protection. Stereotact Funct Neurosurg. 2017;95(5):352-358.
  4. Galbo PM Jr, Ciesielski MJ, Figel S, Maguire O, Qiu J, Wiltsie L, Minderman H, Fenstermaker RA. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017 Oct 10;8(70):114722-114735.
  5. Fenstermaker RA, Figel SA, Qiu J, Barone TA, Dharma SS, Winograd EK, Galbo PM, Wiltsie LM, Ciesielski MJ. Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res. 2018 Jun 1;24(11):2642-2652.
  6. Figel S, Fenstermaker RA. Cell Cycle. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition. San Diego: Academic Press, 2018: 257-267.